Search company, investor...

Predict your next investment

Angel Investor (Individual)
dk.linkedin.com/pub/tommy-ahlers/0/683/112

Investments

17

Portfolio Exits

4

About Tommy Ahlers

Tommy Ahlers is a Europe-based angel investor who is currently CEO at Podio and was formerly founder and CEO at Zyb.com. Zyb was sold to Vodafone in May 2008 for 31.5 million Euros.

Headquarters Location

Denmark

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Tommy Ahlers News

Danish biotech startup secures largest seed funding round in the country’s history

Feb 13, 2023

Copenhagen-based startup Reshape Biotech has made waves by raising $7.1M to add to its $1M seed funding round, creating a new national record of $8.1M. This accomplishment was made possible thanks to the support of Acme Capital , as well as top investors Nicholas Francis , founder of Unity, Per Falholt , and Look Up Ventures , which includes esteemed entrepreneurs Tommy Ahlers and Nicolaj Reffstrup . The startup develops accessible automation solutions that will help leaders in food, agriculture and biologics digitize research and collaborate globally. With the additional funding, Reshape Biotech is looking to expand its product offering and take its already innovative analysis platform to the next level. A member of the Y Combinator 2021 class, Reshape Biotech allows companies to easily digitize microbiology experiments and virtually collaborate on a global scale. Traditionally, lab automation has been extremely expensive and difficult to implement. Reshape is offering affordable robotic instruments by leveraging systems engineering, mechatronics, cloud computing, machine-learning-based data analysis and a deep understanding of biotech applications. Its robots are vertically integrated across hardware, software, and microbiology to accurately capture data while eliminating redundant processes. Reshape currently serves 20 customers including researchers, scientists, lab techs, and CXOs working in agricultural and food microbiology, ingredients development, industrial biotech and more. The power of its technology and service has resulted in 100% customer retention and 300% YoY growth. “Biotech is the most important industry of the 21st century. For it to flourish in the future, we have to make the discovery process more accessible and affordable. Automation at scale is critical to making that a reality,” said Reshape Biotech founder & CEO Carl-Emil Grøn . “We are ‘reshaping’ manual processes that have remained largely unchanged over the last 100 years. Our technology is helping R&D labs troubleshoot in real time with production sites located tens of thousand miles away and letting researchers check results from home, allowing remote work to prosper in lab environments. It’s an efficient approach that better fits the world we live in today.” The Reshape platform creates a new R&D infrastructure for leaders in food, agriculture and biology, enabling digitized research that can be shared to benefit scientists everywhere, regardless of physical lab location. The distributed platform with connected lab equipment empowers scientists and technicians to conduct research 1,000X more rapidly than today. Since 2021, Reshape has grown its robotic fleet from one to 110, experienced 10X revenue growth, and facilitated groundbreaking scientific breakthroughs. “Digitizing laborious processes in research and development for food and biotech industries can lead to healthier societies for people and our planet,” said Tang-Jespersen . “Reshape challenges the status quo of the last century of microbiology experimentation with a cost-efficient product that allows for much higher volume experiments, more meaningful data points, and faster results. This technology has the potential to change the integrity of our food supply, biotech, and more.” Headquartered in Copenhagen, Reshape currently distributes equipment across Europe and the U.S. In the near future, the company plans to open a location in North America and expand development, application science and sales efforts to scale its robotic fleet in the coming years.

Tommy Ahlers Investments

17 Investments

Tommy Ahlers has made 17 investments. Their latest investment was in Ento Labs as part of their Angel on March 3, 2022.

CBI Logo

Tommy Ahlers Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/30/2022

Angel

Ento Labs

Yes

1

5/28/2021

Series A

Worksome

$13M

Yes

5

3/27/2018

Corporate Minority

LABFRESH

$0.1M

Yes

1

3/13/2018

Angel

Subscribe to see more

$99M

Subscribe to see more

10

10/7/2017

Angel

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/30/2022

5/28/2021

3/27/2018

3/13/2018

10/7/2017

Round

Angel

Series A

Corporate Minority

Angel

Angel

Company

Ento Labs

Worksome

LABFRESH

Subscribe to see more

Subscribe to see more

Amount

$13M

$0.1M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

5

1

10

10

Tommy Ahlers Portfolio Exits

4 Portfolio Exits

Tommy Ahlers has 4 portfolio exits. Their latest portfolio exit was Peakon on January 28, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/28/2021

Acquired

$99M

25

7/31/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/14/2016

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

4/11/2012

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/28/2021

7/31/2019

7/14/2016

4/11/2012

Exit

Acquired

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

25

10

10

10

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.